Abstract
Owing to the molecular complexity of cancer and the cost of therapy, researchers have begun looking to in vivo functional genomics to inform patient care. Unfortunately, xenographs of established tumour cell lines in immunodeficient mice fail to recapitulate many critical features of human primary tumours. By contrast, mouse models of cancer often faithfully recapitulate basic biology, tumour–microenvironment interactions, drug responses and therapy resistance similar to human disease. Thus, we established the co-clinical trial project, and in doing so developed the concept of the mouse hospital, whereby in vivo preclinical and early clinical studies are closely aligned, enabling in vivo testing of drugs in a multitude of cancer subtypes using mouse models, while minimizing the cost and time required to study responses in thousands of human patients. This approach can inform enrolment of patients in clinical trials, and can enable repositioning and/or repurposing of previously approved drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
30 April 2015
In the version of this article initially published online, the author line contained a spelling error (Paulo instead of Paolo). The error has been corrected for the print, HTML and PDF versions of the article.
References
Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795–806 (2012).
Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17–37 (2013).
Mendelsohn, J., Tursz, T., Schilsky, R. L. & Lazar, V. WIN Consortium--challenges and advances. Nat. Rev. Clin. Oncol. 8, 133–134 (2011).
Tursz, T., Andre, F., Lazar, V., Lacroix, L. & Soria, J.-C. Implications of personalized medicine--perspective from a cancer center. Nat. Rev. Clin. Oncol. 8, 177–183 (2011).
Lunardi, A. et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat. Genet. 45, 747–755 (2013).
Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613–617 (2012).
Nardella, C., Lunardi, A., Patnaik, A., Cantley, L. C. & Pandolfi, P. P. The APL paradigm and the 'co-clinical trial' project. Cancer Discov. 1, 108–116 (2011).
Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813–823 (2006).
Sharma, S. V., Haber, D. A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241–253 (2010).
Kelland, L. R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40, 827–836 (2004).
Sausville, E. A. & Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351–3354 (2006).
Finn, O. J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23, S6–S9 (2012).
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
Siolas, D. & Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73, 5315–5319 (2013).
Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338–350 (2012).
Malaney, P., Nicosia, S. V. & Davé, V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 344, 1–12 (2014).
Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106, 1565–1573 (2005).
Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477–6489 (2005).
Traggiai, E. et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304, 104–107 (2004).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).
Lunardi, A., Nardella, C., Clohessy, J. G. & Pandolfi, P. P. Of model pets and cancer models: an introduction to mouse models of cancer. Cold Spring Harb. Protoc. 2014, 17–31 (2014).
He, L. Z. et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 18, 126–135 (1998).
Rego, E. M., He, L. Z., Warrell, R. P., Wang, Z. G. & Pandolfi, P. P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl Acad. Sci. USA 97, 10173–10178 (2000).
Ito, K. et al. A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18, 1350–1358 (2012).
Ventura, A. et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875–886 (2008).
Mu, P. et al. Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 23, 2806–2811 (2009).
Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
Ma, L. et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19, 1779–1786 (2005).
Nardella, C. et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22, 2172–2177 (2008).
Nardella, C. et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal 2, ra2 (2009).
Wang, G. et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat. Genet. 45, 739–746 (2013).
Boilève, A. et al. Immunosurveillance against tetraploidization-induced colon tumorigenesis. Cell Cycle 12, 473–479 (2013).
Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).
Tuveson, D. & Hanahan, D. Translational medicine: Cancer lessons from mice to humans. Nature 471, 316–317 (2011).
Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496–1510 (2006).
Regales, L. et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000–3010 (2009).
Clohessy, J. G. & de Stanchina, E. Infrastructure needs for translational integration of mouse and human trials. Cold Spring Harb. Protoc. 2013, 1109–1114 (2013).
MacConaill, L. E. et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4, e7887 (2009).
Gray, S. W., Hicks-Courant, K., Cronin, A., Rollins, B. J. & Weeks, J. C. Physicians' attitudes about multiplex tumor genomic testing. J. Clin. Oncol. 32, 1317–1323 (2014).
Acknowledgements
This work is supported by the NCI grants 5U01CA141457-05 and 5U01CA141496-05 to P.P.P.
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to researching data, discussing content and writing the article, and to review and editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Clohessy, J., Pandolfi, P. Mouse hospital and co-clinical trial project—from bench to bedside. Nat Rev Clin Oncol 12, 491–498 (2015). https://doi.org/10.1038/nrclinonc.2015.62
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.62
This article is cited by
-
The progressive trend of modeling and drug screening systems of breast cancer bone metastasis
Journal of Biological Engineering (2024)
-
Acoustofluidic assembly of primary tumor-derived organotypic cell clusters for rapid evaluation of cancer immunotherapy
Journal of Nanobiotechnology (2023)
-
Design, Development, In Silico, and In Vitro Characterization of Camptothecin-Loaded Mixed Micelles: In Vitro Testing of Verapamil and Ranolazine for Repurposing as Coadjuvant Therapy in Cancer
Journal of Pharmaceutical Innovation (2023)
-
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Journal of Translational Medicine (2022)
-
The cell-line-derived subcutaneous tumor model in preclinical cancer research
Nature Protocols (2022)